Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Thursday
Corvus Pharmaceuticals (NASDAQ:CRVS) is scheduled to issue its Q1 quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.10. On average, analysts expect Corvus Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Corvus Pharmaceuticals stock opened at $4.04 on Wednesday. Corvus Pharmaceuticals has a one year low of $3.22 and a one year high of $13.91.
A number of research firms have recently commented on CRVS. Zacks Investment Research raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Wedbush cut their price target on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $11.94.
ILLEGAL ACTIVITY WARNING: “Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Thursday” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/corvus-pharmaceuticals-crvs-set-to-announce-quarterly-earnings-on-thursday/3001816.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Article: Cash Flow
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.